Wird geladen...
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
OBJECTIVES: Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. METHODS: Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were randomized 1:1 to maraviroc with darunavir/ritonavir qd (...
Gespeichert in:
Veröffentlicht in: | PLoS One |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artigo |
Sprache: | Inglês |
Veröffentlicht: |
Public Library of Science
2017
|
Schlagworte: | |
Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5697828/ https://ncbi.nlm.nih.gov/pubmed/29161288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0187393 |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|